Everolimus is associated with long term benefits such as preventing renal function and reducing the incidence of infections, malignancies and major cardiovascular events. The Certic registry was designed to assess the impsct of Everolimus tretament on patient outcome for at least 5 years in hearth or kidney transdplant recipient form 34 Italian center. Certic is an observational, multicentre, prospective study that included patients on everolimus treatment for at least 6 months.
L. Furian, L. Di Maria, G. Cappelli, M. Carmellini, G. Spagnoletti, G. Piredda, et al. (2016). Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study. AMERICAN JOURNAL OF TRANSPLANTATION, 16(3), 479-479 [10.1111/ajt.13898].
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study
TODESCHINI, PAOLA;
2016
Abstract
Everolimus is associated with long term benefits such as preventing renal function and reducing the incidence of infections, malignancies and major cardiovascular events. The Certic registry was designed to assess the impsct of Everolimus tretament on patient outcome for at least 5 years in hearth or kidney transdplant recipient form 34 Italian center. Certic is an observational, multicentre, prospective study that included patients on everolimus treatment for at least 6 months.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
